Viatris Inc. (NASDAQ: VTRS) Stock Competitors & Peer Comparison
See VTRS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for VTRS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VTRS | $16.43 | +0.86% | 19.1B | 6.52 | $2.52 | +2.90% |
| TAK | $17.45 | +2.53% | 55.5B | 12.55 | $1.39 | +3.61% |
| HLN | $10.03 | +0.00% | 44.2B | 25.11 | $0.40 | +1.76% |
| TEVA | $35.36 | +1.58% | 41.2B | 12.06 | $2.93 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.12 | -8.60% | 11B | 20.86 | $1.06 | N/A |
| RDY | $12.22 | +0.91% | 10.2B | 20.01 | $0.61 | +0.68% |
| LNTH | $100.95 | -0.12% | 6.6B | 16.97 | $5.95 | N/A |
| AMRX | $18.14 | +0.39% | 5.8B | 20.16 | $0.90 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
VTRS vs TAK Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, TAK has a market cap of 55.5B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while TAK trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas TAK's P/E ratio is 12.55. In terms of profitability, VTRS's ROE is -0.03%, compared to TAK's ROE of +0.02%. Regarding short-term risk, VTRS is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check TAK's competition here
Haleon plc (NYSE: HLN)
VTRS vs HLN Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while HLN trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas HLN's P/E ratio is 25.11. In terms of profitability, VTRS's ROE is -0.03%, compared to HLN's ROE of +0.17%. Regarding short-term risk, VTRS is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
VTRS vs TEVA Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, TEVA has a market cap of 41.2B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while TEVA trades at $35.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas TEVA's P/E ratio is 12.06. In terms of profitability, VTRS's ROE is -0.03%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, VTRS is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check TEVA's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
VTRS vs ITCI Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ITCI's P/E ratio is -180.64. In terms of profitability, VTRS's ROE is -0.03%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, VTRS is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
VTRS vs CTLT Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas CTLT's P/E ratio is -27.84. In terms of profitability, VTRS's ROE is -0.03%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, VTRS is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
VTRS vs ELAN Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ELAN has a market cap of 11B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ELAN trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ELAN's P/E ratio is 20.86. In terms of profitability, VTRS's ROE is -0.03%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, VTRS is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
VTRS vs RDY Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while RDY trades at $12.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas RDY's P/E ratio is 20.01. In terms of profitability, VTRS's ROE is -0.03%, compared to RDY's ROE of +0.09%. Regarding short-term risk, VTRS is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
VTRS vs LNTH Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while LNTH trades at $100.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas LNTH's P/E ratio is 16.97. In terms of profitability, VTRS's ROE is -0.03%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, VTRS is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
VTRS vs AMRX Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while AMRX trades at $18.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas AMRX's P/E ratio is 20.16. In terms of profitability, VTRS's ROE is -0.03%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, VTRS is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
VTRS vs INDV Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while INDV trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas INDV's P/E ratio is 10.64. In terms of profitability, VTRS's ROE is -0.03%, compared to INDV's ROE of -2.16%. Regarding short-term risk, VTRS is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
VTRS vs SUPN Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while SUPN trades at $47.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas SUPN's P/E ratio is 15.57. In terms of profitability, VTRS's ROE is -0.03%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, VTRS is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
VTRS vs RGC Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while RGC trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas RGC's P/E ratio is -380.99. In terms of profitability, VTRS's ROE is -0.03%, compared to RGC's ROE of -2.32%. Regarding short-term risk, VTRS is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
VTRS vs BHC Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while BHC trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas BHC's P/E ratio is 1.59. In terms of profitability, VTRS's ROE is -0.03%, compared to BHC's ROE of +0.89%. Regarding short-term risk, VTRS is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
VTRS vs DCPH Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas DCPH's P/E ratio is -11.58. In terms of profitability, VTRS's ROE is -0.03%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, VTRS is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
VTRS vs HCM Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while HCM trades at $12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas HCM's P/E ratio is 4.69. In terms of profitability, VTRS's ROE is -0.03%, compared to HCM's ROE of +0.01%. Regarding short-term risk, VTRS is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
VTRS vs AVDL Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, VTRS's ROE is -0.03%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, VTRS is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
VTRS vs EMBCV Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas EMBCV's P/E ratio is N/A. In terms of profitability, VTRS's ROE is -0.03%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, VTRS is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
VTRS vs DVAX Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas DVAX's P/E ratio is -41.89. In terms of profitability, VTRS's ROE is -0.03%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, VTRS is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
VTRS vs ANIP Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ANIP trades at $78.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ANIP's P/E ratio is 9.52. In terms of profitability, VTRS's ROE is -0.03%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, VTRS is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check ANIP's competition here
Perrigo Company plc (NYSE: PRGO)
VTRS vs PRGO Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while PRGO trades at $12.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas PRGO's P/E ratio is 5.13. In terms of profitability, VTRS's ROE is -0.03%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, VTRS is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check PRGO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
VTRS vs TARO Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas TARO's P/E ratio is 30.05. In terms of profitability, VTRS's ROE is -0.03%, compared to TARO's ROE of +0.03%. Regarding short-term risk, VTRS is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
VTRS vs HROW Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while HROW trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas HROW's P/E ratio is 449.33. In terms of profitability, VTRS's ROE is -0.03%, compared to HROW's ROE of -0.34%. Regarding short-term risk, VTRS is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
VTRS vs PAHC Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while PAHC trades at $34.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas PAHC's P/E ratio is 11.70. In terms of profitability, VTRS's ROE is -0.03%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, VTRS is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
VTRS vs ALVO Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ALVO trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ALVO's P/E ratio is -11.21. In terms of profitability, VTRS's ROE is -0.03%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, VTRS is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
VTRS vs ETON Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ETON trades at $44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ETON's P/E ratio is -637.14. In terms of profitability, VTRS's ROE is -0.03%, compared to ETON's ROE of -0.06%. Regarding short-term risk, VTRS is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
VTRS vs CRON Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while CRON trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas CRON's P/E ratio is 29.44. In terms of profitability, VTRS's ROE is -0.03%, compared to CRON's ROE of +0.06%. Regarding short-term risk, VTRS is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
VTRS vs PCRX Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, PCRX has a market cap of 984.2M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while PCRX trades at $25.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas PCRX's P/E ratio is 9.62. In terms of profitability, VTRS's ROE is -0.03%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, VTRS is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check PCRX's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
VTRS vs COLL Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, COLL has a market cap of 955.8M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while COLL trades at $29.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas COLL's P/E ratio is 3.70. In terms of profitability, VTRS's ROE is -0.03%, compared to COLL's ROE of +0.16%. Regarding short-term risk, VTRS is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check COLL's competition here
PetIQ, Inc. (NASDAQ: PETQ)
VTRS vs PETQ Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas PETQ's P/E ratio is 83.73. In terms of profitability, VTRS's ROE is -0.03%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, VTRS is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
VTRS vs AMPH Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while AMPH trades at $20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas AMPH's P/E ratio is 7.09. In terms of profitability, VTRS's ROE is -0.03%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, VTRS is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check AMPH's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
VTRS vs IRWD Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while IRWD trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas IRWD's P/E ratio is 5.54. In terms of profitability, VTRS's ROE is -0.03%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, VTRS is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
VTRS vs EVO Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, EVO has a market cap of 710.5M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while EVO trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas EVO's P/E ratio is -2.82. In terms of profitability, VTRS's ROE is -0.03%, compared to EVO's ROE of -0.24%. Regarding short-term risk, VTRS is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
VTRS vs BDSI Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas BDSI's P/E ratio is 6.82. In terms of profitability, VTRS's ROE is -0.03%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, VTRS is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
VTRS vs TLRY Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while TLRY trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas TLRY's P/E ratio is -7.21. In terms of profitability, VTRS's ROE is -0.03%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, VTRS is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check TLRY's competition here
Evolus, Inc. (NASDAQ: EOLS)
VTRS vs EOLS Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, EOLS has a market cap of 499.8M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while EOLS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas EOLS's P/E ratio is -24.04. In terms of profitability, VTRS's ROE is -0.03%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, VTRS is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
VTRS vs AQST Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, AQST has a market cap of 494.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while AQST trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas AQST's P/E ratio is -6.46. In terms of profitability, VTRS's ROE is -0.03%, compared to AQST's ROE of +1.91%. Regarding short-term risk, VTRS is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
VTRS vs KMDA Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, KMDA has a market cap of 419.4M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while KMDA trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas KMDA's P/E ratio is 20.77. In terms of profitability, VTRS's ROE is -0.03%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, VTRS is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
VTRS vs CGC Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, CGC has a market cap of 409.5M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas CGC's P/E ratio is -0.58. In terms of profitability, VTRS's ROE is -0.03%, compared to CGC's ROE of -0.31%. Regarding short-term risk, VTRS is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
VTRS vs TKNO Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, TKNO has a market cap of 346.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while TKNO trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas TKNO's P/E ratio is -20.84. In terms of profitability, VTRS's ROE is -0.03%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, VTRS is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
VTRS vs ALIM Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ALIM's P/E ratio is 5.28. In terms of profitability, VTRS's ROE is -0.03%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, VTRS is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
VTRS vs LNDC Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas LNDC's P/E ratio is -4.04. In terms of profitability, VTRS's ROE is -0.03%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, VTRS is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check LNDC's competition here
Embecta Corp. (NASDAQ: EMBC)
VTRS vs EMBC Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, EMBC has a market cap of 262.2M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while EMBC trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas EMBC's P/E ratio is 1.70. In terms of profitability, VTRS's ROE is -0.03%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, VTRS is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check EMBC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
VTRS vs ORGO Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ORGO trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ORGO's P/E ratio is 62.00. In terms of profitability, VTRS's ROE is -0.03%, compared to ORGO's ROE of -0.27%. Regarding short-term risk, VTRS is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
VTRS vs TYHT Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas TYHT's P/E ratio is -1.61. In terms of profitability, VTRS's ROE is -0.03%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, VTRS is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
VTRS vs SIGA Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, SIGA has a market cap of 218.8M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while SIGA trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas SIGA's P/E ratio is 11.30. In terms of profitability, VTRS's ROE is -0.03%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, VTRS is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
VTRS vs LFCR Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, LFCR has a market cap of 187.9M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while LFCR trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas LFCR's P/E ratio is -4.68. In terms of profitability, VTRS's ROE is -0.03%, compared to LFCR's ROE of -1.95%. Regarding short-term risk, VTRS is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check LFCR's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
VTRS vs ACB Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ACB has a market cap of 185.2M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ACB trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ACB's P/E ratio is -6.10. In terms of profitability, VTRS's ROE is -0.03%, compared to ACB's ROE of -0.21%. Regarding short-term risk, VTRS is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check ACB's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
VTRS vs REPH Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas REPH's P/E ratio is -8.04. In terms of profitability, VTRS's ROE is -0.03%, compared to REPH's ROE of -0.22%. Regarding short-term risk, VTRS is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
VTRS vs DERM Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while DERM trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas DERM's P/E ratio is -17.38. In terms of profitability, VTRS's ROE is -0.03%, compared to DERM's ROE of -0.36%. Regarding short-term risk, VTRS is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
VTRS vs CRDL Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, CRDL has a market cap of 163.7M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while CRDL trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas CRDL's P/E ratio is -5.05. In terms of profitability, VTRS's ROE is -0.03%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, VTRS is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
VTRS vs THTX Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas THTX's P/E ratio is -28.83. In terms of profitability, VTRS's ROE is -0.03%, compared to THTX's ROE of +0.17%. Regarding short-term risk, VTRS is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
VTRS vs ASRT Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ASRT's P/E ratio is -7.10. In terms of profitability, VTRS's ROE is -0.03%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, VTRS is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check ASRT's competition here
Organigram Global Inc. (NASDAQ: OGI)
VTRS vs OGI Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, OGI has a market cap of 139.4M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while OGI trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas OGI's P/E ratio is -3.81. In terms of profitability, VTRS's ROE is -0.03%, compared to OGI's ROE of -0.07%. Regarding short-term risk, VTRS is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check OGI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
VTRS vs CPIX Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, CPIX has a market cap of 116.9M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while CPIX trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas CPIX's P/E ratio is -19.50. In terms of profitability, VTRS's ROE is -0.03%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, VTRS is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
VTRS vs SCTL Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas SCTL's P/E ratio is -7.86. In terms of profitability, VTRS's ROE is -0.03%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, VTRS is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
VTRS vs PROC Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas PROC's P/E ratio is 1.53. In terms of profitability, VTRS's ROE is -0.03%, compared to PROC's ROE of -2.22%. Regarding short-term risk, VTRS is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
VTRS vs OPTN Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas OPTN's P/E ratio is -4.42. In terms of profitability, VTRS's ROE is -0.03%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, VTRS is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
VTRS vs ZOM Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ZOM's P/E ratio is -1.62. In terms of profitability, VTRS's ROE is -0.03%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, VTRS is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check ZOM's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
VTRS vs ZYBT Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ZYBT trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, VTRS's ROE is -0.03%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, VTRS is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check ZYBT's competition here
Upexi, Inc. (NASDAQ: GRVI)
VTRS vs GRVI Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas GRVI's P/E ratio is 26.05. In terms of profitability, VTRS's ROE is -0.03%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, VTRS is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
VTRS vs ZYNE Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, VTRS's ROE is -0.03%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, VTRS is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
VTRS vs SSIC Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas SSIC's P/E ratio is 11.93. In terms of profitability, VTRS's ROE is -0.03%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, VTRS is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
VTRS vs VLNS Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas VLNS's P/E ratio is -1.03. In terms of profitability, VTRS's ROE is -0.03%, compared to VLNS's ROE of N/A. Regarding short-term risk, VTRS is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check VLNS's competition here
BGM Group Ltd. (NASDAQ: BGM)
VTRS vs BGM Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, BGM has a market cap of 60.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas BGM's P/E ratio is -1.04. In terms of profitability, VTRS's ROE is -0.03%, compared to BGM's ROE of -0.07%. Regarding short-term risk, VTRS is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check BGM's competition here
DURECT Corporation (NASDAQ: DRRX)
VTRS vs DRRX Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas DRRX's P/E ratio is -4.44. In terms of profitability, VTRS's ROE is -0.03%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, VTRS is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
VTRS vs INCR Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, INCR has a market cap of 58M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while INCR trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas INCR's P/E ratio is -2.26. In terms of profitability, VTRS's ROE is -0.03%, compared to INCR's ROE of -0.09%. Regarding short-term risk, VTRS is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
VTRS vs JUPW Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas JUPW's P/E ratio is -2.41. In terms of profitability, VTRS's ROE is -0.03%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, VTRS is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
VTRS vs QLI Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas QLI's P/E ratio is -4.92. In terms of profitability, VTRS's ROE is -0.03%, compared to QLI's ROE of -0.16%. Regarding short-term risk, VTRS is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
VTRS vs HEXO Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas HEXO's P/E ratio is -0.26. In terms of profitability, VTRS's ROE is -0.03%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, VTRS is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check HEXO's competition here
Talphera, Inc. (NASDAQ: TLPH)
VTRS vs TLPH Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, TLPH has a market cap of 29.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while TLPH trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas TLPH's P/E ratio is -4.61. In terms of profitability, VTRS's ROE is -0.03%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, VTRS is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check TLPH's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
VTRS vs RMTI Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while RMTI trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas RMTI's P/E ratio is -6.89. In terms of profitability, VTRS's ROE is -0.03%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, VTRS is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
VTRS vs AYTU Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while AYTU trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas AYTU's P/E ratio is -1.23. In terms of profitability, VTRS's ROE is -0.03%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, VTRS is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
VTRS vs TXMD Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas TXMD's P/E ratio is 105.45. In terms of profitability, VTRS's ROE is -0.03%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, VTRS is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
VTRS vs CYTH Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas CYTH's P/E ratio is -0.80. In terms of profitability, VTRS's ROE is -0.03%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, VTRS is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
VTRS vs EVOK Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas EVOK's P/E ratio is -7.97. In terms of profitability, VTRS's ROE is -0.03%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, VTRS is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check EVOK's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
VTRS vs BFRIW Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, VTRS's ROE is -0.03%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, VTRS is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check BFRIW's competition here
Optimi Health Corp. (NASDAQ: OPTH)
VTRS vs OPTH Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, OPTH has a market cap of 16.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while OPTH trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas OPTH's P/E ratio is -18.56. In terms of profitability, VTRS's ROE is -0.03%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, VTRS is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
VTRS vs ACRX Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ACRX's P/E ratio is -0.31. In terms of profitability, VTRS's ROE is -0.03%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, VTRS is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
VTRS vs COSM Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while COSM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas COSM's P/E ratio is -0.38. In terms of profitability, VTRS's ROE is -0.03%, compared to COSM's ROE of -0.96%. Regarding short-term risk, VTRS is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
VTRS vs AGRX Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas AGRX's P/E ratio is -0.89. In terms of profitability, VTRS's ROE is -0.03%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, VTRS is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
VTRS vs NLTX Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas NLTX's P/E ratio is -0.28. In terms of profitability, VTRS's ROE is -0.03%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, VTRS is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
VTRS vs LCI Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas LCI's P/E ratio is -0.04. In terms of profitability, VTRS's ROE is -0.03%, compared to LCI's ROE of +1.66%. Regarding short-term risk, VTRS is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
VTRS vs ADMP Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ADMP's P/E ratio is -0.08. In terms of profitability, VTRS's ROE is -0.03%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, VTRS is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
VTRS vs YCBD Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas YCBD's P/E ratio is -1.38. In terms of profitability, VTRS's ROE is -0.03%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, VTRS is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
VTRS vs GELS Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas GELS's P/E ratio is -1.09. In terms of profitability, VTRS's ROE is -0.03%, compared to GELS's ROE of -0.25%. Regarding short-term risk, VTRS is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
VTRS vs MNK Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas MNK's P/E ratio is -0.44. In terms of profitability, VTRS's ROE is -0.03%, compared to MNK's ROE of -0.26%. Regarding short-term risk, VTRS is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
VTRS vs FLGC Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas FLGC's P/E ratio is -0.19. In terms of profitability, VTRS's ROE is -0.03%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, VTRS is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check FLGC's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
VTRS vs CPHI Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while CPHI trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas CPHI's P/E ratio is -1.76. In terms of profitability, VTRS's ROE is -0.03%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, VTRS is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check CPHI's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
VTRS vs UPC Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, UPC has a market cap of 3.5M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while UPC trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas UPC's P/E ratio is -0.69. In terms of profitability, VTRS's ROE is -0.03%, compared to UPC's ROE of -0.03%. Regarding short-term risk, VTRS is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
VTRS vs SBFM Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while SBFM trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas SBFM's P/E ratio is -0.20. In terms of profitability, VTRS's ROE is -0.03%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, VTRS is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check SBFM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
VTRS vs SHPH Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, SHPH has a market cap of 2.6M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while SHPH trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas SHPH's P/E ratio is -0.20. In terms of profitability, VTRS's ROE is -0.03%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, VTRS is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check SHPH's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
VTRS vs PLXP Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas PLXP's P/E ratio is -0.22. In terms of profitability, VTRS's ROE is -0.03%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, VTRS is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check PLXP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
VTRS vs SNOA Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while SNOA trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas SNOA's P/E ratio is -1.22. In terms of profitability, VTRS's ROE is -0.03%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, VTRS is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check SNOA's competition here
Athenex, Inc. (NASDAQ: ATNX)
VTRS vs ATNX Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas ATNX's P/E ratio is -0.02. In terms of profitability, VTRS's ROE is -0.03%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, VTRS is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check ATNX's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
VTRS vs PROCW Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas PROCW's P/E ratio is N/A. In terms of profitability, VTRS's ROE is -0.03%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, VTRS is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
VTRS vs RDHL Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while RDHL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas RDHL's P/E ratio is 0.12. In terms of profitability, VTRS's ROE is -0.03%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, VTRS is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check RDHL's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
VTRS vs YCBD-PA Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, VTRS's ROE is -0.03%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, VTRS is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
VTRS vs CYTHW Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas CYTHW's P/E ratio is N/A. In terms of profitability, VTRS's ROE is -0.03%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, VTRS is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for VTRS.Check CYTHW's competition here
Lucy Scientific Discovery Inc. (NASDAQ: LSDI)
VTRS vs LSDI Comparison August 2026
Viatris Inc. (NASDAQ: VTRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTRS stands at 19.1B. In comparison, LSDI has a market cap of 906.9K. Regarding current trading prices, VTRS is priced at $16.43 on the NASDAQ, while LSDI trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTRS currently has a P/E ratio of 6.52, whereas LSDI's P/E ratio is -0.07. In terms of profitability, VTRS's ROE is -0.03%, compared to LSDI's ROE of +181.47%. Regarding short-term risk, VTRS is less volatile compared to LSDI. This indicates lower risk in terms of short-term price fluctuations for VTRS.Check LSDI's competition here